

Interventional Brain Medicine: Medicine's newest frontier

© The Author(s), under exclusive license to Genomic Press 2024

Brain Medicine; <https://doi.org/10.61373/bm024g.0013>

A New Journal to Bridge a Disadvantageous Gap

Dysfunction of neural cells, or their destruction, are the cause of most neurologic and psychiatric diseases. Which specific networks are involved determines whether there is a neurologic or psychiatric disease (or both, as in most cases). Advances in neuroscience have blurred the artificial boundaries between psychiatry and neurology and have contributed to the momentum toward a long-awaited convergence of these disciplines. Unified clinical training has been proposed (1), but current training in the US and much of Europe continues to follow the divergent approach established in the 19th century. As a result, neurology and psychiatry operate isolated from each other, without explicit or consistent criteria for why a disorder is claimed by one discipline or the other. Pathologic processes that affect purely "neurologic" or "psychiatric" brain circuits are the exception and are not the rule. This split approach hinders access to the best quality care for patients with brain disorders. A new journal has been created with this in mind (2). *Brain Medicine* will embrace an inclusive way forward that uniquely holds the potential to shift current paradigms (2).

A Model of Convergence: Interventional Brain Medicine

There are several areas where the fields are already converging, such as increased neuroimaging of psychiatric disorders (3) or psychotherapeutic techniques being adopted in neurology clinics (4). But perhaps nowhere is the way forward more apparent than with the rapidly advancing treatment modalities of brain stimulation. Indeed, dialogue from experts at a Brain Stimulation Subspecialty Summit (BRASSS) held in Boston in 2023 emphasized an interest in cross-disciplinary implementation. *Interventional Brain Medicine* emerged as the leading name for a potential new medical subspecialty. This name and approach build on literature and existing clinics implementing 'Interventional Psychiatry' (5, 6) but expands these treatment tools to include modulation of any brain network.

The prospective subspecialty, Interventional Brain Medicine, represents the newest frontier and embodies the aim of the new journal, Brain Medicine, which will include publications of results from therapeutic modulation of neural cells and circuits across the brain. We do not present a comprehensive review of these modalities. However, we will highlight how the science and practice behind *Interventional Brain Medicine* serve as a model for bringing neurology and psychiatry together and how it fits into the concept of Brain Medicine as medicine's next frontier.

Neuromodulation, or brain stimulation, refers to techniques that use waveform energy to directly and therapeutically perturb targeted brain regions and networks. Recent advancements in neuromodulation modalities also offer a novel paradigm for understanding the brain. These modalities use electrical, magnetic, acoustic, or optical energy to perturb specific brain regions and networks. They also allow valuable insights into the causal relationships between the brain and behavior on an individual-subject basis. Neuromodulation techniques also help refine neurobiological models of brain disorders and offer therapeutic benefits to patients who cannot improve with conventional treatments.

Various neuromodulation modalities are available as clinical or investigational approaches for treating neurological and psychiatric conditions. These include open-loop deep brain stimulation (DBS) and

responsive neurostimulation (RNS), vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS), transcranial electrical stimulation (tES) [which includes transcranial direct current (tDCS), transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS)], electroconvulsive therapy (ECT), magnetic seizure therapy (MST), epidural cortical stimulation (ECS), spinal cord stimulation (SCS), transcranial/low-intensity focused ultrasound (tFUS/LIFU), and temporal interference (TI). While some novel approaches have promising evidence, we will focus on those already in clinical use to highlight the trans-disciplinary utility and potential of the tools of the emerging subspecialty of *Interventional Brain Medicine*.

Invasive Modalities

Deep Brain Stimulation

Perhaps the most classical approach to neuromodulation is the direct delivery of electrical stimulation to brain tissue. Deep brain stimulation (DBS) is an invasive technique that involves implanting electrodes in specific brain regions and delivering electrical pulses to modulate activity. Currently, DBS is primarily clinically used for movement disorders, including essential tremor, dystonia, Parkinson's disease (7), and epilepsy (8) and, thus, is most often considered a "neurological" treatment. However, within psychiatry, it also has an FDA humanitarian device exemption for obsessive-compulsive disorder (OCD) (9); although underutilized, it has also shown efficacy in some studies and case series in depression, Tourette syndrome (10), and addiction (11). Unfortunately, the expansion of DBS within brain medicine indications has been limited by availability, cost, and apprehension of an invasive procedure, especially by psychiatrists who are not familiar with DBS (12). Awareness is a particular barrier among psychiatrists owing, in part, to a fragmented field where "neurologic" treatments are not widely considered for psychiatric patients, [although many medications developed initially for classical neurological disorders like epilepsy can also treat depression and mood disorders] (13, 14). The future of DBS involves more precise and personalized circuit-based targeting for a broader range of neurological and psychiatric symptoms, closed-loop paradigms that adjust stimulation parameters based on disease biomarkers, and combination therapies that integrate DBS with pharmacological, behavioral, or cognitive interventions (15). While interest in using DBS across the spectrum of Brain Medicine continues to grow, the benefits from these advancements in clinical practice remain mostly limited to patients with "neurological" disease. Notwithstanding, DBS has the potential to offer powerful and trans-diagnostic alternatives for pervasive symptoms of brain circuit disorders.

Responsive Neurostimulation

Responsive neurostimulation (RNS) also involves implanting electrodes in specific brain regions, but unlike DBS, it delivers stimulation only when abnormal activity is trained and detected in a closed-loop fashion. RNS was approved by the FDA in 2013 for the treatment of focal epilepsy that does not respond to medication or surgery (16). RNS disrupts the synchronization of epileptic neurons to restore normal activity patterns (17). While currently only FDA-cleared for epilepsy, there is research





underway to expand the indications for other brain medicine disorders, such as Parkinson's disease, essential tremor, and dystonia, and investigate the long-term effects on neural connectivity and plasticity (18, 19). Promisingly, similar systems are also being evaluated for psychiatric diseases using closed-loop stimulation for depression, binge eating disorder, and OCD (17, 20, 21).

Vagus Nerve Stimulation

Vagus nerve stimulation (VNS) delivers electrical pulses invasively or non-invasively to the neck or to a branch of the vagus, activating brainstem nuclei and causing widespread neurotransmitter release (22). VNS was initially developed in the 1980s as a treatment for refractory epilepsy (23) but was also found to have antidepressant effects and was FDA-cleared for the treatment of major depressive disorder in 2005 (24, 25). It is predominantly still used for refractory epilepsy. However, the emergence of noninvasive systems has led to evaluation for other neuropsychiatric conditions, such as Alzheimer's disease, post-stroke recovery, post-traumatic stress disorder, autism, and addiction, as well as for enhancing cognitive performance, learning, and memory (26). Despite its relatively low risk, along with regulatory approvals for depression, its adoption in clinical practice for depression remains limited. This is likely due to the lack of a convincing Class 1 evidence clinical trial of efficacy in depression, and at least in part due to provider awareness, access, and training in programming the device. Notwithstanding, it has created some inroads in thinking about the brain holistically, especially in guiding treatment for patients with both epilepsy and prominent mood symptoms. This should serve as a pattern for usage as evidence mounts for its efficacy in addressing specific symptoms of brain circuit disorders.

Noninvasive modalities

Electroconvulsive Therapy

Electroconvulsive therapy (ECT) involves the induction of a brief generalized seizure under anesthesia by applying an electrical current through the scalp. While ECT has been used for over 80 years, it remains the most effective and fast-acting treatment for severe and treatment-resistant depression, as well as other mood disorders, catatonia, and psychosis (27). While not typically used in clinical neurology, ECT does have evidence for safety and efficacy in treating Parkinsonism (28) as well as status epilepticus (29). The future of ECT may involve improving its safety and tolerability, refining electrode placement and stimulation parameters, combining it with other therapies, such as transcranial magnetic stimulation (TMS) and ketamine, and better elucidating its mechanisms of action (30–32). Similarly to other modalities, ECT is almost exclusively used by “one side” of Brain Medicine; most neurologists have very little awareness or comfort with using this potentially life-saving therapy in times of need, such as refractory status epilepticus.

Transcranial Magnetic Stimulation

Modern transcranial magnetic stimulation (TMS) was invented in 1985 and approved for the acute treatment of depression in 2008 (33). It is a noninvasive technique that creates electrical activity in the brain via magnetic waves through an electric coil positioned on the surface of the scalp. Through manipulation of stimulation parameters, it can induce long-term potentiation (LTP) or depression (LTD)-like effects, which are thought to exert a top-down effect from cortical areas through the disease network (34, 35). Innovations since its conception have included more efficient delivery systems, various coil designs to shape the induced field to activate specific brain networks, targeting via neuronavigation, and different protocols to deliver more rapid or effective treatment (36–38). Clinically, TMS is mainly used for FDA-cleared psychiatric indications, including depression, OCD, and smoking cessation. However, single-pulse TMS is also FDA-cleared for migraine, and TMS was just recently cleared for pain.

Further, there is evidence for its use in neurodegenerative diseases, movement disorders, epilepsy, and multiple sclerosis (39). In fact (and case in point to highlight our argument), TMS was originally and exclusively used by motor neurophysiologists (40). But a potentially important moment in the development of TMS as an antidepressant occurred when a dual-trained (neurology and psychiatry) physician (M.S.G., author) was

exposed to TMS in a neurology/psychiatry fellowship and “borrowed” this technology for a new area of research and eventually leading to FDA approved indication. With a demonstrated ability to modulate cortical tissue and with a good safety and tolerability profile, it is surprising that TMS has not been adopted for additional indications, especially in neurology. Perhaps too little cross-disciplinary thinking, which the journal *Brain Medicine* aims to address, has limited TMS expansion.

Conclusion

These current FDA-cleared brain stimulation modalities will likely soon be joined by others (e.g., low-intensity focused ultrasound, transcranial direct current stimulation). However, if brain medicine physicians are not exposed to these modalities by cross-disciplinary training, will they be utilized by the “other” specialty (even when FDA-cleared)? How many psychiatrists consider DBS for OCD? How many neurologists consider TMS for migraine? In our experience, the answer is very few. We have highlighted these tools with indications across brain medicine, although they are all dominated by the use of the specialty in which they were first developed. Importantly, this emerging field is just beginning, and many other investigational indications have good evidence and will likely be FDA-cleared. Not all physicians treating brain disorders need to become experts in brain stimulation modalities. However, they need to be aware of these modalities to refer patients who are refractory to treatment or may prefer non-medication treatment approaches. They may be tailored to individual patients and integrated into a comprehensive treatment algorithm for patients with different brain circuit disorders. By increasing the exposure and awareness of different brain stimulation modalities, physicians can genuinely operate with a “full toolbox” for treatment across the spectrum of Brain Medicine. Until we bring these fields together, we are limiting how much we can help patients with novel brain stimulation approaches to brain disease. Indeed, we see *Interventional Brain Medicine*, with its current and rapidly emerging potential for use across disciplines, as a type for other brain subspecialties, where physicians approach diagnostics and treatments without an arbitrary border that inevitably leaves the “other” affected brain cells and circuits underrecognized and undertreated.

Acknowledgements

JB is supported by the Brain & Behavior Research Foundation (#31748) and by the McLean Hospital Center of Excellence in Depression and Anxiety Disorders and by the Department of Defense Advanced Research Projects Agency (HR00112320037); The views, opinions and/or findings expressed are those of the author and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government.

Poojith Nuthalapati¹, Charles Palmer², Daniel A.N. Barbosa², Mark S. George^{2,3}, and Joshua C. Brown^{4,5}

¹Department of Neurology, Comprehensive Epilepsy Center, Yale University School of Medicine, New Haven, Connecticut; ²Department of Psychiatry and Behavioral Sciences and Department of Neurology, Medical University of South Carolina, Charleston; ³Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston; ⁴Psychiatric Neurotherapeutics Program, Division of Depression and Anxiety Disorders, McLean Hospital, Belmont, Massachusetts; ⁵Department of Psychiatry, Harvard Medical School, Boston, Massachusetts

✉ e-mail: jbrown@mclean.harvard.edu

References

1. Brown JC, Dainton-Howard H, Woodward J, Palmer C, Karamchandani M, Williams NR, et al. Time for Brain Medicine. *J Neuropsychiatry Clin Neurosci*. 2023;35(4):333-40. DOI: [10.1176/appi.neuropsych.21120312](https://doi.org/10.1176/appi.neuropsych.21120312).
2. Licinio J. Brain Medicine: Exceptional science, no fiefdoms, and a better tomorrow. *Brain Med*. 2024. DOI: [10.61373/bm024d.0007](https://doi.org/10.61373/bm024d.0007). Online ahead of print
3. First MB, Drevets WC, Carter C, Dickstein DP, Kasoff L, Kim KL, et al. Clinical Applications of Neuroimaging in Psychiatric Disorders. *Am J Psychiatry*. 2018;175(9):915-6. DOI: [10.1176/appi.ajp.2018.1750701](https://doi.org/10.1176/appi.ajp.2018.1750701). PMC6583905.
4. DeGrush E, LaFrance WC. Psychotherapeutic Tools to Enhance the Neurologist-Patient Interaction. *Semin Neurol*. 2022;42(2):107-13. DOI: [10.1055/s-0042-1742288](https://doi.org/10.1055/s-0042-1742288).
5. Brown JC. An Interventional Psychiatry Track. *Am J Psychiatry Resid J*. 2019;15(1):11-4. DOI: [10.1176/appi.ajp-rj.2019.150110](https://doi.org/10.1176/appi.ajp-rj.2019.150110). PMC7255422.



6. Williams NR, Taylor JJ, Snipes JM, Short EB, Kantor EM, George MS. Interventional psychiatry: how should psychiatric educators incorporate neuromodulation into training? *Acad Psychiatry*. 2014;38(2):168-76. DOI: [10.1007/s40596-014-0050-x](https://doi.org/10.1007/s40596-014-0050-x). [PMC4021584](https://pubmed.ncbi.nlm.nih.gov/2421584/).
7. Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. *Lancet Neurol*. 2009;8(1):67-81. DOI: [10.1016/S1474-4422\(08\)70291-6](https://doi.org/10.1016/S1474-4422(08)70291-6).
8. Yan H, Wang X, Zhang X, Qiao L, Gao R, Ni D, et al. Deep brain stimulation for patients with refractory epilepsy: nuclei selection and surgical outcome. *Front Neurol*. 2023;14:1169105. DOI: [10.3389/fneur.2023.1169105](https://doi.org/10.3389/fneur.2023.1169105). [PMC10213517](https://pubmed.ncbi.nlm.nih.gov/410213517/).
9. Visser-Vandewalle V, Andrade P, Mosley PE, Greenberg BD, Schuurman R, McLaughlin NC, et al. Deep brain stimulation for obsessive-compulsive disorder: a crisis of access. *Nat Med*. 2022;28(8):1529-32. DOI: [10.1038/s41591-022-01879-z](https://doi.org/10.1038/s41591-022-01879-z).
10. Kakusa B, Saluja S, Barbosa DAN, Cartmell S, Espil FM, Williams NR, et al. Evidence for the role of the dorsal ventral lateral posterior thalamic nucleus connectivity in deep brain stimulation for Gilles de la Tourette syndrome. *J Psychiatr Res*. 2021;132:60-4. DOI: [10.1016/j.jpsychires.2020.09.024](https://doi.org/10.1016/j.jpsychires.2020.09.024).
11. Ranjan M, Ranjan N, Deogaonkar M, Rezai A. Deep Brain Stimulation for Refractory Depression, Obsessive-Compulsive Disorder and Addiction. *Neurol India*. 2020;68(Supplement):S282-7. DOI: [10.4103/0028-3886.302459](https://doi.org/10.4103/0028-3886.302459).
12. Holtzheimer PE, Mayberg HS. Deep brain stimulation for psychiatric disorders. *Annu Rev Neurosci*. 2011;34:289-307. DOI: [10.1146/annurev-neuro-061010-113638](https://doi.org/10.1146/annurev-neuro-061010-113638).
13. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. *Am J Psychiatry*. 1980;137(7):782-90. DOI: [10.1176/ajp.137.7.782](https://doi.org/10.1176/ajp.137.7.782).
14. Ballenger JC, Post RM. Therapeutic effects of carbamazepine in affective illness: a preliminary report. *Commun Psychopharmacol*. 1978;2(2):159-75.
15. Fenoy AJ, Simpson RK. Risks of common complications in deep brain stimulation surgery: management and avoidance. *J Neurosurg*. 2014;120(1):132-9. DOI: [10.3171/2013.10.JNS131225](https://doi.org/10.3171/2013.10.JNS131225).
16. Morrell MJ, RNS System in Epilepsy Study Group. Responsive cortical stimulation for the treatment of medically intractable partial epilepsy. *Neurology*. 2011;77(13):1295-304. DOI: [10.1212/WNL.0b013e3182302056](https://doi.org/10.1212/WNL.0b013e3182302056).
17. Nho YH, Rolle CE, Topalovic U, Shivacharan RS, Cunningham TN, Hiller S, et al. Responsive deep brain stimulation guided by ventral striatal electrophysiology of obsession durably ameliorates compulsion. *Neuron*. 2024;112(1):73-83.e4. DOI: [10.1016/j.neuron.2023.09.034](https://doi.org/10.1016/j.neuron.2023.09.034). [PMC10841397](https://pubmed.ncbi.nlm.nih.gov/410841397/).
18. Bergey GK, Morrell MJ, Mizrahi EM, Goldman A, King-Stephens D, Nair D, et al. Long-term treatment with responsive nucleus accumbens deep brain stimulation for refractory partial seizures. *Neurology*. 2015;84(8):810-7. DOI: [10.1212/WNL.0000000000001280](https://doi.org/10.1212/WNL.0000000000001280). [PMC4339127](https://pubmed.ncbi.nlm.nih.gov/24339127/).
19. Geller EB. Responsive neurostimulation: Review of clinical trials and insights into focal epilepsy. *Epilepsy Behav*. 2018;88S:11-20. DOI: [10.1016/j.yebeh.2018.06.042](https://doi.org/10.1016/j.yebeh.2018.06.042).
20. Scangos KW, Khambhati AN, Daly PM, Makhoul GS, Sugrue LP, Zamanian H, et al. Closed-loop neuromodulation in an individual with treatment-resistant depression. *Nat Med*. 2021;27(10):1696-700. DOI: [10.1038/s41591-021-01480-w](https://doi.org/10.1038/s41591-021-01480-w).
21. Shivacharan RS, Rolle CE, Barbosa DAN, Cunningham TN, Feng A, Johnson ND, et al. Pilot study of responsive nucleus accumbens deep brain stimulation for loss-of-control eating. *Nat Med*. 2022;28(9):1791-6. DOI: [10.1038/s41591-022-01941-w](https://doi.org/10.1038/s41591-022-01941-w). [PMC9499853](https://pubmed.ncbi.nlm.nih.gov/39499853/).
22. Badran BW, Dowdle LT, Mithoefer OJ, LaBate NT, Coatsworth J, Brown JC, et al. Neurophysiologic effects of transcutaneous auricular vagus nerve stimulation (taVNS) via electrical stimulation of the tragus: A concurrent taVNS/fMRI study and review. *Brain Stimul*. 2018;11(3):492-500. DOI: [10.1016/j.brs.2017.12.009](https://doi.org/10.1016/j.brs.2017.12.009). [PMC6487660](https://pubmed.ncbi.nlm.nih.gov/306487660/).
23. Ben-Menachem E. Vagus-nerve stimulation for the treatment of epilepsy. *Lancet Neurol*. 2002;1(8):477-82. DOI: [10.1016/S1474-4422\(02\)00220-x](https://doi.org/10.1016/S1474-4422(02)00220-x).
24. Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. *Biol Psychiatry*. 2005;58(5):355-63. DOI: [10.1016/j.biopsych.2005.05.024](https://doi.org/10.1016/j.biopsych.2005.05.024).
25. George MS, Rush AJ, Marangell LB, Sackeim HA, Brannan SK, Davis SM, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. *Biol Psychiatry*. 2005;58(5):364-73. DOI: [10.1016/j.biopsych.2005.07.028](https://doi.org/10.1016/j.biopsych.2005.07.028).
26. Hulsey DR, Riley JR, Loerwald KW, Rennaker RL, Kilgard MP, Hays SA. Parametric characterization of neural activity in the locus coeruleus in response to vagus nerve stimulation. *Exp Neurol*. 2017;289:21-30. DOI: [10.1016/j.expneurol.2016.12.005](https://doi.org/10.1016/j.expneurol.2016.12.005). [PMC5297969](https://pubmed.ncbi.nlm.nih.gov/297969/).
27. Kellner CH, Greenberg RM, Murrrough JW, Bryson EO, Briggs MC, Pasculli RM. ECT in treatment-resistant depression. *Am J Psychiatry*. 2012;169(12):1238-44. DOI: [10.1176/appi.ajp.2012.12050648](https://doi.org/10.1176/appi.ajp.2012.12050648).
28. Takamiya A, Seki M, Kudo S, Yoshizaki T, Nakahara J, Mimura M, et al. Electroconvulsive Therapy for Parkinson's Disease: A Systematic Review and Meta-Analysis. *Mov Disord*. 2021;36(1):50-8. DOI: [10.1002/mds.28335](https://doi.org/10.1002/mds.28335).
29. San-Juan D, Dávila-Rodríguez DO, Jiménez CR, González MS, Carranza SM, Hernández Mendoza JR, et al. Neuromodulation techniques for status epilepticus: A review. *Brain Stimul*. 2019;12(4):835-44. DOI: [10.1016/j.brs.2019.04.005](https://doi.org/10.1016/j.brs.2019.04.005).
30. Sackeim HA. Modern Electroconvulsive Therapy: Vastly Improved yet Greatly Underused. *JAMA Psychiatry*. 2017;74(8):779-80. DOI: [10.1001/jamapsychiatry.2017.1670](https://doi.org/10.1001/jamapsychiatry.2017.1670).
31. Loo CK, Mitchell PB. A review of the efficacy of transcranial magnetic stimulation (TMS) treatment for depression, and current and future strategies to optimize efficacy. *J Affect Disord*. 2005;88(3):255-67. DOI: [10.1016/j.jad.2005.08.001](https://doi.org/10.1016/j.jad.2005.08.001).
32. Deng ZD, Luber B, McClintock SM, Weiner RD, Husain MM, Lisanby SH. Clinical Outcomes of Magnetic Seizure Therapy vs Electroconvulsive Therapy for Major Depressive Episode: A Randomized Clinical Trial. *JAMA Psychiatry*. 2024;81(3):240-9. DOI: [10.1001/jamapsychiatry.2023.4599](https://doi.org/10.1001/jamapsychiatry.2023.4599). [PMC10701670](https://pubmed.ncbi.nlm.nih.gov/410701670/).
33. George MS, Taylor JJ, Short EB. The expanding evidence base for rTMS treatment of depression. *Curr Opin Psychiatry*. 2013;26(1):13-8. DOI: [10.1097/YCO.0b013e32835ab46d](https://doi.org/10.1097/YCO.0b013e32835ab46d). [PMC4214363](https://pubmed.ncbi.nlm.nih.gov/24214363/).
34. Brown JC, Higgins ES, George MS. Synaptic Plasticity 101: The Story of the AMPA Receptor partial agonist, d-cycloserine, enhances 10 Hz rTMS-induced motor plasticity, suggesting long-term potentiation (LTP) as underlying mechanism. *Brain Stimul*. 2020;13(3):530-2. DOI: [10.1016/j.brs.2020.01.005](https://doi.org/10.1016/j.brs.2020.01.005). [PMC7224691](https://pubmed.ncbi.nlm.nih.gov/32724691/).
35. Brown JC, DeVries WH, Korte JE, Sahlem GL, Bonilha L, Short EB, et al. NMDA receptor partial agonist, d-cycloserine, enhances 10 Hz rTMS-induced motor plasticity, suggesting long-term potentiation (LTP) as underlying mechanism. *Brain Stimul*. 2020;13(3):530-2. DOI: [10.1016/j.brs.2020.01.005](https://doi.org/10.1016/j.brs.2020.01.005). [PMC7224691](https://pubmed.ncbi.nlm.nih.gov/32724691/).
36. Cole EJ, Phillips AL, Bentzley BS, Stimpson KH, Nejad R, Barmak F, et al. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. *Am J Psychiatry*. 2022;179(2):132-41. DOI: [10.1176/appi.ajp.2021.20101429](https://doi.org/10.1176/appi.ajp.2021.20101429).
37. Caulfield KA, Brown JC. The Problem and Potential of TMS' Infinite Parameter Space: A Targeted Review and Road Map Forward. *Front Psychiatry*. 2022;13:867091. DOI: [10.3389/fpsy.2022.867091](https://doi.org/10.3389/fpsy.2022.867091). [PMC9127062](https://pubmed.ncbi.nlm.nih.gov/39127062/).
38. Siddiqi SH, Fox MD. Targeting Symptom-Specific Networks With Transcranial Magnetic Stimulation. *Biol Psychiatry*. 2024;95(6):502-9. DOI: [10.1016/j.biopsych.2023.11.011](https://doi.org/10.1016/j.biopsych.2023.11.011).
39. Soman FA, de Graaf TA, Sack AT. Transcranial Magnetic Stimulation in the Treatment of Neurological Diseases. *Front Neurol*. 2022;13:793253. DOI: [10.3389/fneur.2022.793253](https://doi.org/10.3389/fneur.2022.793253). [PMC9163300](https://pubmed.ncbi.nlm.nih.gov/39163300/).
40. Ziemann U. Thirty years of transcranial magnetic stimulation: where do we stand? *Exp Brain Res*. 2017;235(4):973-84. DOI: [10.1007/s00221-016-4865-4](https://doi.org/10.1007/s00221-016-4865-4).

Publisher's note: Genomic Press maintains a position of impartiality and neutrality regarding territorial assertions represented in published materials and affiliations of institutional nature. As such, we will use the affiliations provided by the authors, without editing them. Such use simply reflects what the authors submitted to us and it does not indicate that Genomic Press supports any type of territorial assertions.



Open Access. This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). The license mandates: (1) Attribution: Credit must be given to the original work, with a link to the license and notification of any changes. The acknowledgment should not imply licensor endorsement. (2) NonCommercial: The material cannot be used for commercial purposes. (3) NoDerivatives: Modified versions of the work cannot be distributed. (4) No additional legal or technological restrictions may be applied beyond those stipulated in the license. Public domain materials or those covered by statutory exceptions are exempt from these terms. This license does not cover all potential rights, such as publicity or privacy rights, which may restrict material use. Third-party content in this article falls under the article's Creative Commons license unless otherwise stated. If use exceeds the license scope or statutory regulation, permission must be obtained from the copyright holder. For complete license details, visit <https://creativecommons.org/licenses/by-nc-nd/4.0/>. The license is provided without warranties.